Ex-Sepracor chief to lead startup biotech

Share this article:

Mark Iwicki, previously president and CEO of Sepracor, has signed on as chief executive officer with oncology-focused pipeline biopharma Blend Therapeutics. This news comes in tandem with the announcement that Blend has secured $16 million in Series B financing. Blend received $2.8 million last year when the company was first established.

The Massachusetts-based firm hopes to deliver a safer platinum-based chemotherapy through a delivery vehicle with nanoparticles.

In an interview with Xconomy, Iwicki said the funds will allow the company to operate through drug development for another two years, during which time Blend hopes to file an investigational drug application with the FDA.

Iwicki joined Sepracor in 2007 as EVP, chief commercial officer. Two years later, when Sepracor was acquired by Dainippon Sumitomo Pharmaceuticals and became Sunovion, Iwicki took the reins as chief executive officer.

The acquisition was motivated by Dainippon Sumitomo's desire to bring schizophrenia treatment Latuda to market by way of Sepracor's existing CNS marketing and sales infrastructure.  Latuda won approval in October 2010 amidst a crowded antipsychotic therapeutic category.

In our October, 2006 issue MM&M listed Iwicki as one of our '15 on the rise.' One of his nominators aptly noted, “He is going to run a drug company one day.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...